These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 29874151)
1. Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo. Wang XS; Zhang L; Li X; Kong DJ; Hu XC; Ding XZ; Yang JQ; Zhao MQ; He Y; Lam KS; Gao SG; Lin TY; Li Y Nanomedicine (Lond); 2018 May; 13(10):1107-1120. PubMed ID: 29874151 [TBL] [Abstract][Full Text] [Related]
2. Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. Shi P; Oh YT; Deng L; Zhang G; Qian G; Zhang S; Ren H; Wu G; Legendre B; Anderson E; Ramalingam SS; Owonikoko TK; Chen M; Sun SY Clin Cancer Res; 2017 Nov; 23(21):6567-6579. PubMed ID: 28765329 [No Abstract] [Full Text] [Related]
4. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722 [TBL] [Abstract][Full Text] [Related]
5. AZD9291 Increases Sensitivity to Radiation in PC-9-IR Cells by Delaying DNA Damage Repair after Irradiation and Inducing Apoptosis. Wu S; Zhu L; Tu L; Chen S; Huang H; Zhang J; Ma S; Zhang S Radiat Res; 2018 Mar; 189(3):283-291. PubMed ID: 29332537 [TBL] [Abstract][Full Text] [Related]
6. Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery. Li Y; Xiao K; Luo J; Xiao W; Lee JS; Gonik AM; Kato J; Dong TA; Lam KS Biomaterials; 2011 Sep; 32(27):6633-45. PubMed ID: 21658763 [TBL] [Abstract][Full Text] [Related]
7. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma. Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294 [TBL] [Abstract][Full Text] [Related]
8. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. Jänne PA; Yang JC; Kim DW; Planchard D; Ohe Y; Ramalingam SS; Ahn MJ; Kim SW; Su WC; Horn L; Haggstrom D; Felip E; Kim JH; Frewer P; Cantarini M; Brown KH; Dickinson PA; Ghiorghiu S; Ranson M N Engl J Med; 2015 Apr; 372(18):1689-99. PubMed ID: 25923549 [TBL] [Abstract][Full Text] [Related]
9. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells. Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261 [TBL] [Abstract][Full Text] [Related]
10. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. Remon J; Planchard D Future Oncol; 2015 Nov; 11(22):3069-81. PubMed ID: 26450446 [TBL] [Abstract][Full Text] [Related]
11. A natural anthraquinone derivative shikonin synergizes with AZD9291 against wtEGFR NSCLC cells through reactive oxygen species-mediated endoplasmic reticulum stress. Hu X; Zhang ZY; Wu LW; Zeng LH; Chen H; Zhu HJ; Zhang JK; Shao J; Zhang C; Li YL; Lin NM Phytomedicine; 2020 Mar; 68():153189. PubMed ID: 32070867 [TBL] [Abstract][Full Text] [Related]
12. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo. Liu Z; Gao W Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382 [TBL] [Abstract][Full Text] [Related]
13. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cross DA; Ashton SE; Ghiorghiu S; Eberlein C; Nebhan CA; Spitzler PJ; Orme JP; Finlay MR; Ward RA; Mellor MJ; Hughes G; Rahi A; Jacobs VN; Red Brewer M; Ichihara E; Sun J; Jin H; Ballard P; Al-Kadhimi K; Rowlinson R; Klinowska T; Richmond GH; Cantarini M; Kim DW; Ranson MR; Pao W Cancer Discov; 2014 Sep; 4(9):1046-61. PubMed ID: 24893891 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor. Kim TM; Song A; Kim DW; Kim S; Ahn YO; Keam B; Jeon YK; Lee SH; Chung DH; Heo DS J Thorac Oncol; 2015 Dec; 10(12):1736-44. PubMed ID: 26473643 [TBL] [Abstract][Full Text] [Related]
15. Enhanced Anti-Brain Metastasis from Non-Small Cell Lung Cancer of Osimertinib and Doxorubicin Co-Delivery Targeted Nanocarrier. Wang X; Mao W; Wang Z; Li X; Xiong Y; Lu H; Wang X; Yin H; Cao X; Xin H Int J Nanomedicine; 2020; 15():5491-5501. PubMed ID: 32848385 [TBL] [Abstract][Full Text] [Related]
16. Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype. Xu J; Zhao X; He D; Wang J; Li W; Liu Y; Ma L; Jiang M; Teng Y; Wang Z; Gu M; Wu J; Wang Y; Yue W; Zhang S J Cancer Res Clin Oncol; 2018 Aug; 144(8):1413-1422. PubMed ID: 29797219 [TBL] [Abstract][Full Text] [Related]
17. Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo. Chen S; Zhang Z; Zhang J Drug Des Devel Ther; 2019; 13():1145-1153. PubMed ID: 31114158 [No Abstract] [Full Text] [Related]
18. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539 [TBL] [Abstract][Full Text] [Related]
19. SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met. Tong M; Gao M; Xu Y; Fu L; Li Y; Bao X; Fu H; Quan H; Lou L Cancer Sci; 2019 Nov; 110(11):3584-3594. PubMed ID: 31446643 [TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Zhang W; Shi Y; Chen Y; Yu S; Hao J; Luo J; Sha X; Fang X Eur J Pharm Biopharm; 2010 Aug; 75(3):341-53. PubMed ID: 20451605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]